Nanobiotix (0QAV) Stock Statistics & Valuation Metrics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 1.43B. The enterprise value is EUR 1.56B.
- Market Cap
- EUR 1.43B
- Enterprise Value
- EUR 1.56B
Share Statistics
Nanobiotix has 50,967,610 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 50,967,610
- Owned by Insiders
- ―
- Owned by Institutions
- 6.65%
Financial Efficiency
Nanobiotix’s return on equity (ROE) is 0.28 and return on invested capital (ROIC) is -74.29%.
- Return on Equity (ROE)
- 0.28
- Return on Assets (ROA)
- -0.35
- Return on Invested Capital (ROIC)
- -74.29%
- Return on Capital Employed (ROCE)
- -1.06
- Revenue Per Employee
- 302.48K
- Profits Per Employee
- -244.50K
- Employee Count
- 98
- Asset Turnover
- 0.44
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Nanobiotix is -25.56. Nanobiotix’s PEG ratio is 0.21.
- PE Ratio
- -25.56
- PS Ratio
- 167.44
- PB Ratio
- -41.18
- Price to FCF
- -36.67
- Price to Operating Cash Flow
- -36.13
- PEG Ratio
- 0.21
Income Statement
In the last 12 months, Nanobiotix had revenue of 29.64M and earned -23.96M in profits. Earnings per share was -0.51.
- Revenue
- 29.64M
- Gross Profit
- 29.64M
- Operating Income
- -10.82M
- Pretax Income
- -23.96M
- Net Income
- -23.96M
- EBITDA
- -12.07M
- Earnings Per Share (EPS)
- -0.51
Cash Flow
In the last 12 months, operating cash flow was -38.04M and capital expenditures -1.02M, giving a free cash flow of -39.06M billion.
- Operating Cash Flow
- -38.04M
- Free Cash Flow
- -39.06M
- Free Cash Flow per Share
- -0.80
Dividends & Yields
Nanobiotix pays an annual dividend of EUR 0.29, resulting in a dividend yield of ―
- Dividend Per Share
- EUR 0.29
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.73%
- Earnings Yield
- -3.85%
Stock Price Statistics
- Beta
- 0.56
- 52-Week Price Change
- 74.29%
- 50-Day Moving Average
- 28.23
- 200-Day Moving Average
- 29.40
- Relative Strength Index (RSI)
- 57.38
- Average Volume (3m)
- 11.64K
Important Dates
Nanobiotix upcoming earnings date is Apr 27, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 24, 2026
- Next Earnings Date
- Apr 27, 2027
- Ex-Dividend Date
- Mar 15, 2022
Financial Position
Nanobiotix as a current ratio of 1.09, with Debt / Equity ratio of -112.83%
- Current Ratio
- 1.09
- Quick Ratio
- 1.09
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- -3.53
- Interest Coverage Ratio
- -1.04
Taxes
In the past 12 months, Nanobiotix has paid 3,000 in taxes.
- Income Tax
- 3,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
Nanobiotix EV to EBITDA ratio is -43.80, with an EV/FCF ratio of -36.56.
- EV to Sales
- 166.94
- EV to EBITDA
- -43.80
- EV to Free Cash Flow
- -36.56
- EV to Operating Cash Flow
- -37.55
Balance Sheet
Nanobiotix has EUR 110.89M in cash and marketable securities with EUR 106.61M in debt, giving a net cash position of EUR 4.28M billion.
- Cash & Marketable Securities
- EUR 110.89M
- Total Debt
- EUR 106.61M
- Net Cash
- EUR 4.28M
- Net Cash Per Share
- EUR 0.08
- Tangible Book Value Per Share
- -EUR 0.68
Margins
Gross margin is 100.00%, with operating margin of -367.66%, and net profit margin of -617.88%.
- Gross Margin
- 100.00%
- Operating Margin
- -367.66%
- Pretax Margin
- -639.97%
- Net Profit Margin
- -617.88%
- EBITDA Margin
- -381.12%
- EBIT Margin
- -399.82%
Analyst Forecast
The average price target for Nanobiotix is EUR 60.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 60.00
- Price Target Upside
- 112.77% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―